TICKERNERD
Menu
HROWHROWHealthcare · Drug Manufacturers - Specialty & Generic

HROW Stock Forecast: Harrow, Inc. Price Predictions for 2026-2027

Last close, 25 Aug 2026
$41
+3.84% on the day

The 8 Wall Street analysts covering Harrow, Inc. hold a median 12-month price target of $62 — +48.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 24 Aug 2026 — in the upper half.

Market cap
$1.5B
Ticker Nerd rank
50 / 100
Median analyst target
$62
Analysts covering
8
Revenue$44.2M−7.6% y/y
Operating income−$22.1M
Net income−$27.6M
Free cash flow−$27.2M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.6%
1M
+7.5%
YTD
−15.7%
1Y
+10.6%
From 52W high
−24.6%
From 52W low
+42.4%
$29
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HROW stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Harrow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Aug 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Value
79
Accruals
71
Momentum
58
Growth
42
Size
40
Volatility
39
Revisions
32
Issuance
16

Quality (94): The business earns solid, repeatable profits on what it owns.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HROW stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HROW, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70$80$90Oct 25Jan 26Apr 26Jul 26HROWHigh $88Median $62Low $59

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $59Median $62High $88

The green dot is the last close — the median target sits +48.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026BTIGReiteratesBuy$63
21 July 2026BTIGReiteratesBuy$63
21 July 2026BTIGReiteratesBuy—
13 May 2026Cantor FitzgeraldMaintainsOverweight—
13 May 2026Cantor FitzgeraldMaintainsOverweight$91 → $88
12 May 2026BTIGReiteratesBuy—
12 May 2026BTIGReiteratesBuy$63
17 Apr 2026BTIGReiteratesBuy—
7 Apr 2026B. Riley SecuritiesReiteratesBuy—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
18 Mar 2026BTIGReiteratesBuy—
4 Mar 2026Cantor FitzgeraldMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
12 Nov 2025Ladenburg ThalmannMaintainsBuy—
1 Oct 2025B. Riley SecuritiesReiteratesBuy—
29 Sept 2025BTIGReiteratesBuy—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
29 Sept 2025Lake StreetMaintainsBuy—
24 Sept 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HROW appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HROW vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 25 Aug 2026, Harrow, Inc. returned +10.6% against +20.5% for the S&P 500, dividends included.

HROW vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Oct 25Jan 26Apr 26Jul 26HROWS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HROW analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−36.8%
Analysts raising
1
Analysts cutting
0
Fundamentals

Harrow, Inc. (HROW) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−280.4×

Cheaper than 99% of US stocks

Price / sales
5.3×

Cheaper than 24% of US stocks

Price / book
96.4×

Cheaper than 1% of US stocks

EV / EBITDA
98.8×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
10.9%

Higher than 55% of US stocks

Earnings growth (YoY)
−7.6%

Higher than 28% of US stocks

Gross margin
61.2%

Higher than 75% of US stocks

Operating margin
−15.6%

Higher than 23% of US stocks

Net margin
−13.5%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−116.1%

Higher than 11% of US stocks

Return on assets
−0.5%

Higher than 42% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Harrow, Inc. (HROW) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Harrow, Inc. has a market value of $1.5B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 31 Mar 2026: $268.7M. The latest quarter grew 10.9% year on year.

  • Net income over the same four quarters: −$15.0M, a −5.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.41.

  • Free cash flow in the twelve months to 31 Mar 2026: −$3.9M, after $911K of capital spending.

  • Shares outstanding: 37.3M.

  • Trailing P/E: −280.4×; forward P/E: 14.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Harrow, Inc. employs 373 people — $720K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

HROW vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
HROWHarrow, Inc.$1.5B
50
PAHCPhibro Animal Health Corp.$1.4B
89
XERSXeris Biopharma Holdings, Inc.$1.6B
87
ANIPANI Pharmaceuticals, Inc.$1.7B
94
ETONEton Pharmaceuticals, Inc.$1.8B
99
PRGOPerrigo Co. Plc$2.0B
71
ALVOAlvotech$2.0B
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Harrow, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HROW news & analysis

Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half

Benzinga · 21 Aug 2026positive

Harrow Inc. reported results from a prospective, randomized, contralateral-eye clinical study showing that its Iheezo product reduced eye-injection discomfort by more than half. The announcement was shared on Thursday and highlights the ophthalmic disease management company's clinical data.

Why it matters — A HROW watcher would care because positive clinical results for Iheezo could support the product's positioning and commercial prospects.

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

GlobeNewsWire · 20 Aug 2026positive

Harrow announced patient-reported data for IHEEZO following intravitreal injections, indicating approximately 58% less overall discomfort in the IHEEZO-treated eye, with the largest differences in the immediate post-injection period when discomfort is highest.

Why it matters — Harrow watchers would care because positive discomfort-reduction data for IHEEZO could support the product's clinical profile in the ophthalmology space.

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Seeking Alpha · 13 Aug 2026positive

Seeking Alpha upgraded Harrow from Hold to a cautious Buy following Q2 executional improvements and better visibility on operating leverage, citing improved VEVYE revenue and record IHEEZO demand.

Why it matters — The upgrade reflects growing confidence in Harrow's operational turnaround and revenue growth from its key products.

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seeking Alpha published the transcript of Harrow, Inc.'s Q2 2026 earnings call. The item is a plain transcript with no accompanying analysis or commentary.

Why it matters — Harrow watchers use earnings-call transcripts to review management's own discussion of quarterly results and outlook directly.

Harrow Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

Harrow reported second-quarter revenue of $70.7 million, an 11% increase year-over-year and roughly 60% sequentially, driven by stronger product demand, improved pricing, and expanded commercial infrastructure.

Why it matters — The revenue growth signals that Harrow's commercial strategy and product demand are gaining momentum heading into the second half of 2025.

FAQ

Frequently asked questions about HROW stock

What is the HROW stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Harrow, Inc. have a median 12-month price target of $62, with estimates ranging from $59 to $88. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HROW stock a buy right now?

Of the 8 analysts covering Harrow, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Harrow, Inc. 50 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HROW?

As at 24 Aug 2026, Harrow, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will HROW stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +48.8% from the last close, and Ticker Nerd's factor model ranks Harrow, Inc. 50 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HROW stock forecast for 2030?

No analyst covering Harrow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HROW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $59 to $88 over the next 12 months.

How has HROW stock performed over the past year?

Harrow, Inc. returned +10.6% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Harrow, Inc. do?

Harrow Inc. is an eyecare pharmaceutical company focused on discovering, developing, and commercializing ophthalmic pharmaceutical products for the U.S.

What is the latest news on HROW?

The most recent item we track (Benzinga, 21 Aug 2026): "Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half". Harrow Inc. reported results from a prospective, randomized, contralateral-eye clinical study showing that its Iheezo product reduced eye-injection discomfort by more than half. The announcement was shared on Thursday and highlights the ophthalmic disease management company's clinical data.

Company

About Harrow, Inc.

Harrow Inc. is an eyecare pharmaceutical company focused on discovering, developing, and commercializing ophthalmic pharmaceutical products for the U.S. market. The company operates through two primary business segments: The Branded segment, which includes FDA-approved ophthalmology pharmaceutical products such as IHEEZO, IOPIDINE, VEVYE, ZERVIATE, MAXITROL, ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, FLAREX, TRIESENCE, and NATACYN; and The ImprimisRx segment, representing its ophthalmology-focused pharmaceutical compounding business. These products address various eye conditions, including pain and inflammation from cataract surgery, bacterial conjunctivitis, inflammatory conditions, fungal infections, and ophthalmic diseases requiring steroid treatment. Founded in 1998 and headquartered in Nashville, Tennessee, Harrow helps eyecare professionals preserve vision by making prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans through its comprehensive portfolio.

CEO Mr. Mark L. Baum J.D. · 373 employees · United States · https://www.harrow.com